Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11937730 | 0.81 | XDH (0.55) | NPSR1 | |
| SCHEMBL30405499 | 0.79 | TSHR (0.63) | TSHRNPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL4911079 | 0.77 | HTT (0.46) | TSHRMEN1KMT2AALDH1A1ALOX12 | |
| SCHEMBL27830392 | 0.76 | TSHR (0.59) | TSHRNPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL3568443 | 0.75 | ADORA1 (0.51) | TSHRNPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL6103728 | 0.73 | TSHR (0.56) | TSHRNPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL2031411 | 0.73 | TSHR (0.56) | TSHRNPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL11337983 | 0.72 | ADORA1 (0.54) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL27830395 | 0.71 | TSHR (0.54) | TSHRNPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL161588 | 0.71 | ADORA2A (0.47) | TSHRMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341775-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2341775-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8415346-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415346-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415346-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2341775-A1 | INHIBITORS OF JANUS KINASES | Merck & Co., Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110130393-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130393-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130393-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-06-02 | — | — | US | disclosed |
| WO-2010014453-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2006033995-A2 | THIAZOLIDIN-4-ONES HAVING ANTI-HEPATITIS B ACTIVITY | VALEANT RESEARCH AND DEVELOPMENT (US) | 2006-03-30 | — | — | WO | disclosed |
| US-6331555-B1 | EVALUATING SUSCEPTIBILITY OF CANCER TO COMPOUNDS WHICH INHIBIT PLATELET DERIVED GROWTH FACTOR RECEPTOR ACTIVITY | UNIVERSITY OF CALIFORNIA | 2001-12-18 | — | — | US | disclosed |
| EP-1000617-A2 | Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor | Sugen, Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| US-5990141-A | ADMINISTERING 5-METHYL-ISOXAZOLE-4-CARBOXYLIC ACID-N-(4-TRIFLUOROMETHYL)ANILIDE OR 2-CYANO-3-HYDROXY-N-(4-TRIFLUORO-METHYL)PHENYL-2-BUTENAMIDE; ANTITUMOR,-CARCINOGENIC AND PROLIFERATIVE AGENTS; KINASE INHIBITORS | SUGEN INC. (US) | 1999-11-23 | — | — | US | disclosed |
| US-5958959-A | ADMINISTERING 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID-(4-TRIFLUOROMETHYL)ANILIDE OR 2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHYL)PHENYL)-2-BUTENAMIDE | SUGEN, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5932602-A | ANTIGROWTH AGENTS; ANTITUMOR AGENT; USING AN ISOOXIDAZOLE COMPOUND | SUGEN, INC. (US) | 1999-08-03 | — | — | US | disclosed |
| US-5700822-A | ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF ISOXAZOLE AMIDE DERIVATIOVE AND CYANO, HYDROXY, AROMATIC AMIDE DERIVATIVE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0804191-A1 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCERS USING INHIBITORS OF PLATELET DERIVED GROWTH RECEPTOR | Sugen, Inc. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1995019169-A2 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCER USING INHIBITORS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR | SUGEN, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1994026260-A1 | METHODS AND COMPOUNDS FOR INHIBITING CELL PROLIFERATIVE DISORDERS CHARACTERIZED BY ABNORMAL abl ACTIVITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM 46 Jabotinsky Street (IL) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130393-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | TSHR 1389/4885NPSR1 4059/4885MEN1 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.